Yesterday, September 24, the FDA approved the combination of belzutifan (WELIREG; Merck) plus lenvatinib (LENVIMA; Eisai) to ...
The FDA approved belzutifan in combination with lenvatinib for adults with advanced renal cell carcinoma with a clear cell component following treatment with a PD-1 or PD-L1 inhibitor.The combination ...
US FDA approves Welireg plus Lenvima for certain previously treated adult patients with advanced RCC with a clear cell component: Rahway, New Jersey Monday, September 28, 2026, 14 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results